Editas Medicine, Inc.
Long
Updated

crispr crispr

696
Follow up idea, see related idea

After 5 wave impulse down and two month accumulation phase below IPO level sideways,
expect trend reversal into bull market, the downtrend channel got broken and tested on weekly timeframe.
The first human got crispered in china. USA will follow in 2017, I speculate on public awareness and solid growth, maybe hype.

In case of bull market, we got the possible pitchfork
Note
and back above IPO!!! i love it <3
Note
look for rsi breakout into new highs, consolidation above 18$ would confirm reversal.

snapshot
Note
Wyckoff scenario
snapshot
Note
wyckoff playing out nicely, can buy on dips for reaccumulation 16-17$ range
trailing stop below pitchfork, this stock keeps giving for weeks now with great volatility
Note
made a little indicator to compare EDIT price with the BTK biotech index
At ipo the indicator is 0, values below 0 indicates that EDIT is undervalued compared to biotech index, values over 0 indicates EDIT is overvalued compared to biotech index. Also showing the MA20 of this line (black).

snapshot
Note
crispr again in the news after
Note
crispr again on all news sites after National Academy of Sciences releases Report "Human Genome Editing: Science, Ethics, and Governance"
Note
CRISPR patent goes to Broad Institute of Cambridge -> EDIT technologyreview.com/s/603662/patent-office-hands-win-in-crispr-battle-to-broad-institute/
Note
pitchfork still intact!

wyckoff scenario also playing out as expected :-)

snapshot
Note
Editas Medicine announces that its offering of 4M shares priced at $22.50 per share.
seekingalpha.com/news/3251923-editas-medicine-prices-90m-offering

resistance 0.5 fib keylevel at 28.20
Support 20.00-22.50
Note
doubled my position here
Note
this should be a bear trap, new chart on linear scale
Editas bear trap

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.